{
  "id": "neutropenia",
  "title": "Neutropenia",
  "lang": "en",
  "source_lang": "en",
  "summary": "Neutropenia is a reduced circulating neutrophil count, with causes ranging from inherited variation to marrow disease and treatment-related suppression.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Neutrophil deficiency",
    "Neutrophil granulocytopenia"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/neutropenia/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/neutropenia/",
      "json": "https://aiwiki.page/zh/neutropenia.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Neutropenia is a reduction in the number of circulating neutrophils, white blood cells that provide an important early defense against bacterial and fungal infection. It is a laboratory finding and clinical condition rather than a single disease. Its causes include temporary changes during viral illness, medication effects, immune-mediated destruction, inherited disorders, and diseases affecting the bone marrow. Some persistently low neutrophil counts reflect inherited variation in blood-cell distribution and are not associated with increased infection risk.\n\nThe clinical significance of neutropenia depends on its depth, duration, and mechanism, together with the condition of other immune defenses and protective tissue barriers. A mildly reduced count in an otherwise healthy person differs substantially from a similarly measured count during intensive chemotherapy. Severe, prolonged neutropenia can permit rapidly progressive infection, particularly when accompanied by damage to the mouth or gastrointestinal lining.\n\nAssessment therefore involves more than comparing a blood result with a reference interval. Age, previous counts, medication exposure, associated blood abnormalities, infection history, and relevant genetic findings help distinguish transient or constitutional states from disorders requiring specific treatment. Advances in molecular diagnosis and neutrophil growth-factor therapy have substantially changed the classification and outcomes of severe chronic forms."
    },
    {
      "heading": "Definition, measurement, and severity",
      "text": "Neutropenia is usually defined using the absolute neutrophil count, abbreviated ANC, obtained from a complete blood count with a white-cell differential. The ANC measures the number of neutrophils per unit volume of blood, rather than their percentage among white blood cells. When calculated manually, it includes mature segmented neutrophils and band forms:\n\n\\[\\mathrm{ANC}=\\mathrm{white\\ blood\\ cell\\ count}\\times \\frac{\\%\\mathrm{segmented\\ neutrophils}+\\%\\mathrm{bands}}{100}.\\]\n\nFor example, a white-cell count of \\(2.0\\times10^9/L\\), with 30% segmented neutrophils and 5% bands, gives an ANC of \\(0.7\\times10^9/L\\), equivalent to 700 cells per microliter. A normal neutrophil percentage can therefore coexist with neutropenia when the total white-cell count is low. Conversely, a low percentage does not necessarily indicate a low absolute count.\n\nA commonly used adult threshold is an ANC below \\(1.5\\times10^9/L\\), although some laboratories and classification systems use a lower reference boundary nearer \\(1.8\\times10^9/L\\). Conventional severity categories are mild, approximately \\(1.0–1.5\\times10^9/L\\); moderate, \\(0.5–1.0\\times10^9/L\\); and severe, below \\(0.5\\times10^9/L\\). Counts below \\(0.2\\times10^9/L\\) represent particularly profound neutropenia. Agranulocytosis usually denotes a very severe deficiency of circulating granulocytes, predominantly neutrophils, but its numerical definition varies across clinical and drug-safety literature.\n\nThese categories are useful descriptors rather than universal predictions of infection. Many widely quoted risk relationships were established in people receiving cancer chemotherapy, whose mucosal barriers and other immune functions may also be impaired. People with isolated neutropenia and otherwise intact host defenses may have less infection risk at the same ANC. The presence or absence of an adequate marrow reserve also matters: the circulating count does not directly measure the body's total supply of mature neutrophils.\n\nDuration provides another classification. Neutropenia lasting more than three months is generally called chronic; shorter episodes are described as acute or transient, depending on context. A single measurement does not establish chronic disease because counts fluctuate with infection, physical exertion, stress, medications, and time of day. Age-specific reference intervals are important in infancy and childhood, while neonatal interpretation also depends on gestational and postnatal age. Thus, both the laboratory definition and its clinical meaning require an appropriate reference population and a longitudinal view."
    },
    {
      "heading": "Neutrophil production, distribution, and loss",
      "text": "Neutrophils are part of the innate immune system. They migrate toward sites of tissue injury or infection, ingest microorganisms, and kill them through antimicrobial proteins, granule enzymes, and reactive oxygen species. Their abundance and rapid recruitment make them especially important against many bacterial and fungal pathogens. Their activity also contributes to inflammation, so neutrophil number alone does not capture every aspect of their protective or tissue-damaging effects.\n\nNeutrophils arise from hematopoietic stem and progenitor cells in the marrow through granulopoiesis. Developing cells pass through myeloblast, promyelocyte, myelocyte, metamyelocyte, band, and segmented stages. Early precursors divide, whereas later cells mature without further division. The marrow contains a reserve of mature cells that can be released during infection. Granulocyte colony-stimulating factor—G-CSF—is a central regulator of this process, promoting precursor survival and proliferation, maturation, and release into blood.\n\nOnly part of the body's neutrophil population is measured in an ordinary blood sample. Some neutrophils circulate freely; others interact transiently with vascular endothelium in a marginated pool. Cells also move into tissues and are cleared after completing their functions. Changes in distribution can therefore alter the measured ANC without a corresponding failure of production. Hormonal responses to stress and the effects of corticosteroids, for example, can increase circulating counts partly through redistribution rather than simply through newly generated cells.\n\nMechanistically, neutropenia can result from reduced production, ineffective maturation, increased destruction, accelerated consumption, sequestration, or altered trafficking. Cytotoxic treatment can suppress dividing precursors. Certain inherited disorders interrupt maturation at an early stage. Immune mechanisms can shorten neutrophil survival or affect their precursors. Severe infection may consume cells faster than the marrow can replace them. Enlargement of the spleen can contribute to sequestration, often alongside reductions in other blood-cell populations.\n\nThe categories frequently overlap. A medication may directly injure marrow precursors, trigger an immune response, or act through more than one pathway. Systemic infection can combine altered distribution, consumption, and impaired marrow output. Marrow examination may help distinguish a paucity of precursors from maturation arrest or compensatory production, but the findings are not always specific. Interpretation is strongest when cellular morphology is considered together with the clinical time course, medication history, and molecular or immunological findings. This mechanistic approach explains why identical ANCs can arise from biologically different conditions and carry different prognoses."
    },
    {
      "heading": "Acquired causes",
      "text": "Acquired neutropenia is more common than severe inherited neutropenia. In clinical practice, major categories include medication effects, infection, nutritional deficiency, immune-mediated disease, and acquired marrow disorders. The setting strongly influences their relative frequency: transient postinfectious neutropenia is common in children, whereas treatment-related suppression is prominent in oncology. Isolated neutropenia has a different differential diagnosis from neutropenia accompanied by anemia and a reduced platelet count.\n\nCytotoxic chemotherapy predictably reduces neutrophil production by damaging proliferating marrow precursors. For many conventional regimens, the lowest count occurs roughly 7–14 days after treatment, although timing and duration vary substantially with the drugs, doses, schedule, and marrow reserve. Radiation therapy can also suppress production when a substantial volume of active marrow is exposed. Hematologic malignancy, previous treatment, and marrow infiltration can deepen or prolong the reduction.\n\nOther medications can cause uncommon, sometimes abrupt, severe neutropenia that is not a routine extension of their intended therapeutic action. Recognized examples include clozapine, antithyroid drugs such as methimazole and propylthiouracil, sulfasalazine, and some antimicrobial agents. Prolonged exposure to certain beta-lactam antibiotics can be associated with neutropenia. Mechanisms differ among drugs and include direct toxicity and immune-mediated injury. Some monoclonal antibodies, notably rituximab, can be associated with delayed neutropenia after the treatment course, making the exposure timeline particularly important.\n\nViral infections commonly produce transient reductions. Examples include influenza, Epstein–Barr virus infection, and several other systemic viral illnesses. HIV infection can cause neutropenia through effects on marrow function, associated infections, medications, and other mechanisms. Overwhelming bacterial infection may also produce neutropenia, especially when consumption exceeds production or marrow function is impaired. In that setting, a low count can accompany severe systemic illness rather than indicate protection from inflammation.\n\nDeficiencies of vitamin B12, folate, or copper can impair blood-cell production. Nutritional causes frequently affect more than one cell lineage, and copper deficiency can produce marrow changes that resemble a clonal marrow disorder. Excessive zinc exposure is one recognized cause of copper depletion. Severe malnutrition may contribute through several interacting deficiencies and physiological effects.\n\nAcquired marrow diseases include aplastic anemia, myelodysplastic syndromes, leukemia, and infiltration by other malignant or nonmalignant processes. Clues may include abnormal cell morphology, additional cytopenias, or changes in red-cell size. Disorders causing splenic enlargement, including some cases of cirrhosis, can produce neutropenia through sequestration, often together with thrombocytopenia. These associations make the rest of the blood count and the broader clinical picture essential to causal interpretation."
    },
    {
      "heading": "Inherited neutropenia and cyclic disorders",
      "text": "Inherited neutropenias comprise genetically diverse disorders affecting cell maturation, survival, metabolism, or trafficking. They may be isolated hematologic conditions or components of syndromes involving other organs. Presentation in infancy or early childhood, recurrent bacterial infections, persistent severe counts, congenital abnormalities, or a family history can suggest an inherited cause. However, absence of affected relatives does not exclude one: recessive inheritance and new genetic variants can produce apparently sporadic disease.\n\nSevere congenital neutropenia is characterized by persistent marked neutropenia, often with an ANC below \\(0.5\\times10^9/L\\), and susceptibility to serious infection beginning early in life. Marrow examination commonly shows a block in neutrophil maturation near the promyelocyte or myelocyte stage. Rolf Kostmann described an autosomal recessive form in 1956. The term “Kostmann disease” is now often reserved for the HAX1-associated form rather than used for every severe congenital neutropenia.\n\nVariants in ELANE, the gene encoding neutrophil elastase, account for a substantial proportion of severe congenital and cyclic neutropenia. Other implicated genes include HAX1, G6PC3, JAGN1, and CSF3R. Their effects are not interchangeable: they can disturb intracellular protein handling, cellular metabolism, signaling, or survival. Associated abnormalities vary by genotype. Some HAX1 variants are associated with neurological features, while G6PC3 deficiency may include cardiovascular or urogenital abnormalities.\n\nCyclic neutropenia is distinguished by recurring oscillations in neutrophil production, typically with a cycle of about 21 days. During the nadir, counts may become profoundly low for several days, accompanied by oral ulcers, fever, or bacterial infection; between nadirs, the count and clinical condition can improve substantially. ELANE variants are common. Because an isolated sample may fall anywhere in the cycle, repeated blood counts several times weekly for approximately six weeks are often used during diagnostic evaluation to demonstrate the pattern.\n\nSeveral multisystem disorders include neutropenia. Shwachman–Diamond syndrome combines marrow dysfunction with pancreatic exocrine insufficiency and skeletal abnormalities. Glycogen storage disease type Ib causes metabolic disease with neutropenia and impaired neutrophil function. WHIM syndrome involves warts, hypogammaglobulinemia, infections, and myelokathexis, in which mature neutrophils are abnormally retained in marrow; many cases involve gain-of-function variants in CXCR4.\n\nPrecise molecular classification matters because the long-term risks differ. Several forms of severe congenital neutropenia carry increased risks of myelodysplastic syndrome and acute myeloid leukemia, whereas cyclic neutropenia generally has a different malignant-risk profile. Genetic findings can also identify associated organ involvement and distinguish disorders that look similar on the initial blood count."
    },
    {
      "heading": "Immune-mediated, idiopathic, and Duffy-associated states",
      "text": "Immune-mediated neutropenia includes conditions in which antibodies or immune cells interfere with neutrophil survival or production. Autoimmune neutropenia can occur by itself or alongside a systemic autoimmune disease. The underlying biology is not always captured by a single antibody test: circulating antibody concentrations may be low, relevant targets may be difficult to reproduce in the laboratory, and cellular immune mechanisms may contribute.\n\nPrimary autoimmune neutropenia of infancy usually presents in young children, often with strikingly low counts but fewer severe infections than the ANC alone might suggest. A preserved marrow reserve and otherwise effective host defenses help explain this discrepancy. Many cases resolve spontaneously over the following few years. This natural history differs from that of severe congenital neutropenia, despite possible overlap in the measured count. In neonatal alloimmune neutropenia, maternal antibodies directed against fetal neutrophil antigens cross the placenta; the condition generally resolves as transferred antibodies disappear.\n\nIn adults, immune-associated neutropenia may occur with systemic lupus erythematosus or other autoimmune disorders. Felty syndrome classically combines rheumatoid arthritis, neutropenia, and splenic enlargement. T-cell large granular lymphocytic leukemia is another important association, sometimes occurring with rheumatoid arthritis and chronic neutropenia. Distinguishing these disorders can require blood-cell immunophenotyping and assessment for a clonal lymphocyte population rather than reliance on the neutrophil count alone.\n\nChronic idiopathic neutropenia describes persistent neutropenia without an identified cause after appropriate evaluation. It overlaps biologically and clinically with some forms labeled autoimmune because available testing cannot always demonstrate the immune mechanism. The term does not specify a single molecular disease. Many affected adults have stable isolated neutropenia, while others experience clinically important infections. New abnormalities in other blood-cell lineages or a changing clinical pattern can alter the diagnostic interpretation.\n\nDuffy-null-associated neutrophil count is an important constitutional explanation for lower circulating counts. A common regulatory variant in ACKR1, historically called the Duffy antigen receptor for chemokines gene, prevents its expression on red blood cells while preserving expression in other relevant tissues. This genotype is frequent in populations with ancestry from parts of sub-Saharan Africa and also occurs in some Middle Eastern populations. It is associated with lower circulating ANCs without the infection susceptibility characteristic of marrow failure.\n\nThe older expression “benign ethnic neutropenia” grouped people by broad ancestry labels, which are imprecise proxies for genotype. Duffy-associated terminology more directly identifies a biological association. Neither ancestry nor a Duffy-null result explains every low count, particularly when neutropenia is new, unusually severe, symptomatic, or accompanied by other abnormalities. Its recognition nevertheless helps prevent an inherited reference-range difference from being mistaken for acquired marrow disease."
    },
    {
      "heading": "Clinical manifestations and infectious complications",
      "text": "Neutropenia itself generally causes no distinctive sensation or symptom. Many cases are discovered incidentally on a blood test. Clinical manifestations usually arise from its cause or from infections that become more likely when neutrophil defense is inadequate. Risk is especially increased when the ANC remains below \\(0.5\\times10^9/L\\), and becomes greater with deeper and longer-lasting reductions. Mucosal injury, vascular catheters, underlying malignancy, and additional immunosuppression further modify that risk.\n\nThe mouth, skin, respiratory tract, and perianal region are common sites of infection. Recurrent mouth ulcers, gingivitis, periodontitis, sore throat, and skin infections can be prominent in chronic severe disease. Deep bacterial infections may include pneumonia, bloodstream infection, and invasive soft-tissue infection. Neutrophils are a major component of pus, so profoundly neutropenic patients may produce little purulent material. Redness, swelling, and other inflammatory findings may also be less conspicuous than expected.\n\nFebrile neutropenia is a defined clinical syndrome, especially important in cancer care. A widely used definition combines a single oral temperature of at least \\(38.3^\\circ\\mathrm{C}\\), or a temperature of at least \\(38.0^\\circ\\mathrm{C}\\) sustained for an hour, with an ANC below \\(0.5\\times10^9/L\\) or expected to fall below that level shortly. Institutional definitions differ slightly. Fever may be the only early indication of a serious infection, although severe infection can occasionally occur without it.\n\nBacterial pathogens include organisms from both skin and gastrointestinal flora. Gram-negative bacteria, including Pseudomonas aeruginosa and members of the Enterobacterales, can cause rapidly progressive bloodstream infection. Gram-positive organisms are also frequent, particularly in the presence of vascular access devices or mucosal injury. The distribution of pathogens varies with local resistance patterns, previous antimicrobial exposure, and treatment setting. A substantial proportion of febrile episodes have no microbiologically documented source despite systematic investigation.\n\nProlonged profound neutropenia increases susceptibility to invasive fungal disease, including infections caused by Candida and Aspergillus species. The duration of neutropenia is particularly important for invasive mold infection. Neutropenic enterocolitis, also called typhlitis, is a serious complication associated with bowel-wall injury, inflammation, and infection, often involving the cecum. It can present with fever and abdominal pain and may progress to perforation or systemic infection.\n\nWhen infection triggers organ dysfunction, it constitutes sepsis. Profound neutropenia can make early recognition difficult because local signs are muted and deterioration may be rapid. These features explain why febrile neutropenia is treated as a time-sensitive medical syndrome rather than simply as a low blood count accompanied by an elevated temperature."
    },
    {
      "heading": "Diagnostic evaluation",
      "text": "Evaluation begins by establishing whether the finding is persistent and whether it is isolated. Repeat counts and previous laboratory records distinguish a longstanding baseline from a recent decline. The differential count and blood film can reveal immature cells, abnormal nuclear morphology, circulating blasts, or changes suggesting a broader marrow process. Concurrent anemia, thrombocytopenia, or macrocytosis substantially changes the differential diagnosis.\n\nThe medical history supplies a timeline. Relevant details include recent infection, all prescription and nonprescription exposures, previous chemotherapy or radiotherapy, and the relationship between symptoms and count changes. Recurrent oral ulcers or infections from childhood may suggest an inherited or cyclic condition. A family history can identify a shared pattern, while pancreatic symptoms, growth abnormalities, or congenital malformations may indicate a multisystem syndrome. Autoimmune symptoms and prior blood-count abnormalities provide different diagnostic clues.\n\nPhysical examination focuses on evidence of infection and systemic disease. Oral and periodontal findings can reveal chronic consequences of neutrophil deficiency. Lymph-node enlargement or splenomegaly may point toward immune, infectious, or lymphoid disorders. Abnormal growth or characteristic skeletal and other congenital findings can be informative in children. The absence of such findings does not establish a benign cause, but it contributes to the overall probability of competing explanations.\n\nLaboratory investigations are selected according to the presentation. They may include nutritional measurements, testing for relevant viral infections, autoimmune studies, and assessment of immunoglobulins. Flow cytometry can help identify abnormal lymphocyte populations, including those associated with large granular lymphocytic disorders. Antineutrophil antibody testing can support an immune diagnosis but has technical limitations, including false-negative and false-positive results. It is not a definitive standalone method for distinguishing autoimmune from congenital neutropenia.\n\nA marrow aspirate and biopsy can assess cellularity, maturation, dysplasia, infiltration, and blast numbers. Cytogenetic and molecular studies may identify a clonal marrow disorder. Marrow examination is particularly informative in otherwise unexplained severe neutropenia, additional cytopenias, or suspicious blood-film findings. It is not automatically necessary for every stable, mild, isolated reduction with an established constitutional explanation.\n\nGenetic testing has become central when congenital disease is suspected. Multigene panels can distinguish overlapping syndromes, although variants of uncertain significance require careful interpretation. Serial counts are especially important for suspected cyclic neutropenia because a genetic finding alone does not replace demonstration of the clinical pattern. ACKR1-related testing can clarify an appropriate constitutional explanation. Across these investigations, diagnosis depends on concordance between the observed phenotype, the time course, and the laboratory findings rather than on any one isolated result."
    },
    {
      "heading": "Treatment and supportive care",
      "text": "Treatment is determined by the cause and by the burden of infection, not by the ANC alone. Stable constitutional reductions do not require the same interventions as marrow failure or chemotherapy-associated neutropenia. Reversible causes may improve when the responsible medication is withdrawn, a documented deficiency is corrected, or the underlying disorder is treated. In clinical practice, attribution to a medication includes consideration of competing causes and the known timing of the suspected reaction.\n\nFebrile neutropenia is managed through rapid assessment and empirical antimicrobial treatment while microbiological investigations proceed. Initial regimens generally include activity against Pseudomonas and other important gram-negative pathogens. Selection depends on clinical stability, organ function, previous colonization or infection, allergies, and local resistance data. Additional gram-positive coverage is used for particular indications rather than automatically for every episode. Persistent fever during prolonged neutropenia can lead to evaluation for invasive fungal infection and consideration of antifungal treatment.\n\nRisk-stratification systems help distinguish selected clinically stable patients from those requiring inpatient care. Relevant factors include the expected duration and depth of neutropenia, associated illnesses, hemodynamic status, infection focus, and practical capacity for close follow-up. Such systems complement rather than replace clinical assessment. Microbiological results and the subsequent course guide changes in therapy, linking neutropenic infection management to antimicrobial stewardship and the problem of antimicrobial resistance.\n\nRecombinant G-CSF, including filgrastim and longer-acting formulations such as pegfilgrastim, stimulates neutrophil production. It is used to prevent or shorten clinically important chemotherapy-associated neutropenia in defined settings. In oncology, primary prophylaxis is commonly considered when a regimen carries an approximately 20% or greater risk of febrile neutropenia, or at lower regimen-level risk when additional patient factors increase overall risk. Secondary prophylaxis may be used after a prior neutropenic complication.\n\nG-CSF is also an important treatment for severe congenital, cyclic, and selected other chronic neutropenias with significant infections. Dosing and scheduling differ from the short courses used in many chemotherapy regimens. Bone pain is a common adverse effect; splenic enlargement and other uncommon complications are recognized. Long-term assessment includes infection control, blood counts, treatment response, and risks associated with the underlying disorder. It is not routine treatment for every low count.\n\nHematopoietic stem cell transplantation can provide definitive treatment for selected severe inherited disorders, particularly with inadequate growth-factor response or malignant transformation, but carries substantial treatment-related risks. Granulocyte transfusions have a limited, specialized role in selected severe infections because collection, compatibility, short cell survival, and uncertain efficacy constrain their use. Antimicrobial prophylaxis and infection-prevention measures likewise vary with the expected risk and clinical setting."
    },
    {
      "heading": "Natural history, epidemiology, and research",
      "text": "There is no single prognosis for neutropenia. Transient infection-associated cases often resolve as the illness subsides. Many childhood autoimmune cases remit, while chronic idiopathic neutropenia may remain stable for years. Treatment-associated neutropenia follows the effects of the regimen and the capacity of marrow to recover. Severe inherited disorders can involve lifelong infection susceptibility, associated organ disease, and, in some subtypes, a risk of clonal evolution. These trajectories are sufficiently different that pooling them into one survival estimate would be misleading.\n\nPopulation estimates also depend heavily on definitions. The selected ANC threshold, age distribution, medication exposure, and frequency of Duffy-null genotypes all influence measured prevalence. Hospital-based studies disproportionately capture cancer treatment and severe illness, whereas population surveys detect many asymptomatic low counts. Severe congenital neutropenia and cyclic neutropenia are rare, and much of their long-term evidence comes from specialist registries rather than large population samples.\n\nThe development of recombinant G-CSF in the 1980s and its clinical adoption around the beginning of the 1990s changed the course of severe chronic neutropenia. Before effective growth-factor treatment, recurrent bacterial infections were a major source of illness and death in severe congenital disease. Longitudinal registries subsequently documented improved infection control and made it possible to examine outcomes over decades. They also demonstrated why inherited, cyclic, autoimmune, and idiopathic neutropenia should not be treated as a single prognostic category.\n\nA central research issue is the relationship among congenital marrow biology, treatment response, and malignant evolution. In severe congenital neutropenia, acquired alterations involving CSF3R and other leukemia-associated genes can arise during follow-up. Changes involving RUNX1 and additional drivers may accompany progression toward myelodysplastic syndrome or acute myeloid leukemia. A single detected clone does not inevitably mean transformation, and the significance depends on the mutation pattern, clone size, blood counts, and marrow findings. Observational associations between high G-CSF requirements and adverse outcomes are difficult to separate from the severity of the underlying disease.\n\nGenotype-specific treatment is another developing area. In WHIM syndrome, targeting abnormal CXCR4 signaling addresses the retention of neutrophils in marrow rather than merely stimulating their production. Mavorixafor, an oral CXCR4 antagonist, received United States approval in 2024 for patients aged 12 years and older with WHIM syndrome to increase circulating mature neutrophils and lymphocytes. This represents a mechanism-directed approach applicable to a defined rare disorder, not a general treatment for all neutropenia.\n\nResearch on reference intervals is also changing disease classification. Incorporating ACKR1 genotype and better-characterized healthy populations can distinguish constitutional low counts from pathological neutropenia more accurately than broad ancestry categories. This distinction affects eligibility criteria in drug studies, interpretation of treatment-related blood changes, and the identification of genuine toxicity in people whose baseline counts fall below conventional laboratory limits."
    }
  ],
  "links": [
    "neutrophil",
    "bone-marrow",
    "chemotherapy",
    "complete-blood-count",
    "agranulocytosis",
    "immune-system",
    "bacteria",
    "inflammation",
    "granulocyte-colony-stimulating-factor",
    "corticosteroid",
    "spleen",
    "anemia",
    "radiation-therapy",
    "beta-lactam-antibiotic",
    "monoclonal-antibody",
    "influenza",
    "epstein-barr-virus",
    "hiv-aids",
    "vitamin-b12",
    "folate",
    "malnutrition",
    "aplastic-anemia",
    "myelodysplastic-syndrome",
    "leukemia",
    "cirrhosis",
    "gene",
    "autoimmune-disease",
    "systemic-lupus-erythematosus",
    "rheumatoid-arthritis",
    "blood-test",
    "immunosuppression",
    "periodontitis",
    "pneumonia",
    "fever",
    "abdominal-pain",
    "sepsis",
    "differential-diagnosis",
    "medical-history",
    "physical-examination",
    "biopsy",
    "antimicrobial-resistance",
    "hematopoietic-stem-cell-transplantation",
    "prevalence"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}